Gag mutations strongly contribute to HIV-1 resistance to protease inhibitors in highly drug-experienced patients besides compensating for fitness loss.
Human immunodeficiency virus type 1 (HIV-1) resistance to protease inhibitors (PI) results from mutations in the viral protease (PR) that reduce PI binding but also decrease viral replicative capacity (RC). Additional mutations compensating for the RC loss subsequently accumulate within PR and in Ga...
Main Authors: | Elisabeth Dam, Romina Quercia, Bärbel Glass, Diane Descamps, Odile Launay, Xavier Duval, Hans-Georg Kräusslich, Allan J Hance, François Clavel, ANRS 109 Study Group |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2009-03-01
|
Series: | PLoS Pathogens |
Online Access: | http://europepmc.org/articles/PMC2652074?pdf=render |
Similar Items
-
Role of Gag in HIV Resistance to Protease Inhibitors
by: Fabrizio Mammano, et al.
Published: (2010-07-01) -
Computational identification of novel amino-acid interactions in HIV Gag via correlated evolution.
by: Olga V Kalinina, et al.
Published: (2012-01-01) -
Modulation of HIV-1 infectivity and cyclophilin A-dependence by Gag sequence and target cell type
by: Dam Elisabeth, et al.
Published: (2009-03-01) -
Human Immunodeficiency Virus gag and protease: partners in resistance
by: Fun Axel, et al.
Published: (2012-08-01) -
Reviewing HIV-1 Gag Mutations in Protease Inhibitors Resistance: Insights for Possible Novel Gag Inhibitor Designs
by: Chinh Tran-To Su, et al.
Published: (2019-09-01)